| Identification | Back Directory | [Name]
BPR1J-340 | [CAS]
1395051-72-5 | [Synonyms]
BPR1J-340
N-(3-(4-[([(5-ethyl-3-isoxazolyl)amino]carbonylamino)methyl]phenyl)-1H-5-pyrazolyl)-4-[(4-methylpiperazino)methyl]benzamide | [Molecular Formula]
C29H34N8O3 | [MOL File]
1395051-72-5.mol | [Molecular Weight]
542.63 |
| Hazard Information | Back Directory | [Description]
BPR1J-340 is a potent and selective FLT3 inhibitor with potential anticancer activity. BPR1J-340 was identified as a novel potent FLT3 inhibitor by biochemical kinase activity (IC50 approximately 25 nM) and cellular proliferation (GC50 approximately 5 nM) assays. BPR1J-340 inhibited the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD(+) AML cells. The pharmacokinetic parameters of BPR1J-340 in rats were determined. BPR1J-340 also demonstrated pronounced tumor growth inhibition and regression in FLT3-ITD(+) AML murine xenograft models. The combination treatment of the HDAC inhibitor vorinostat (SAHA) with BPR1J-340 synergistically induced apoptosis via Mcl-1 down-regulation in MOLM-13 AML cells, indicating that the combination of selective FLT3 kinase inhibitors and HDAC inhibitors could exhibit clinical benefit in AML therapy. | [Uses]
BPR1J-340 is a potent FLT3 inhibitor with an IC50 of ~25 nM. BPR1J-340 inhibits the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD+ acute myeloid leukemia (AML) cells. BPR1J-340 exhibits significant anti-tumor activities[1]. | [References]
[1] Wen-Hsing Lin, et al. Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer. PLoS One. 2014 Jan 8;9(1):e83160. DOI:10.1371/journal.pone.0083160 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|